Research and Markets (http://www.researchandmarkets.com/research/tvv2gf/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL).

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope of the Report:

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Companies Mentioned:

  • 4SC AG
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hutchison MediPharma Limited
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Innate Pharma SA
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • LFB S.A.
  • Lymphocyte Activation Technologies, S.A.
  • Medicenna Therapeutics, Inc
  • MedImmune, LLC
  • Millennium Pharmaceuticals, Inc.
  • MorphoSys AG
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Portola Pharmaceuticals, Inc.
  • Sanofi
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/tvv2gf/refractory